Evidence map›Paper›PMID 39886491›Full record

ArticleBMJ oncology2023

Gender disparities in clinical outcomes of urothelial carcinoma linked to X chromosome gene

Zhaopei Liu, Kaifeng Jin, Ziyue Xu, Jingtong Xu, Xiaohe Su, Bingyu Li, Ge Liu, Hailong Liu, Yuan Chang, Yiwei Wang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zhaopei Liu *Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Kaifeng Jin *NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Ziyue Xu *NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Jingtong Xu *Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Xiaohe SuNHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Bingyu LiDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Ge LiuNHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Hailong LiuDepartment of Urology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yuan ChangDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yiwei WangDepartment of Urology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Le XuDepartment of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Weijuan ZhangDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Zewei WangDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yu ZhuDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Jiejie XuNHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.ORCID 0000-0001-7431-9063

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Methods and analysis: We enrolled 2438 patients with UC from seven independent real-world cohorts possessing comprehensive clinical and genomic data. Point mutations and homozygous deletions of Results: Conclusion: Our findings offer preliminary clinical evidence accentuating

Indexed as

bladder cancerchemotherapygenetic markersimmunotherapytumour biomarkers

Identifiers

PMID39886491
PMCPMC11234999

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.